Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Reuters
Reuters
Business

Modi's ministers choose 'Made in India' vaccine over AstraZeneca

FILE PHOTO: Indian Health Minister Harsh Vardhan holds a dose of Bharat Biotech's COVID-19 vaccine called COVAXIN, during a vaccination campaign at All India Institute of Medical Sciences (AIIMS) hospital in New Delhi, India, January 16, 2021. REUTERS/Adnan Abidi/File Photo

Government ministers and officials were following Prime Minister Narendra Modi lead by opting on Tuesday for an Indian-made COVID-19 vaccine approved without late-stage efficacy data, instead of the AstraZeneca one.

India's health, foreign and law ministers, and state governors, all flocked to Twitter to express support for the much-criticised Bharat Biotech's COVAXIN vaccine, after it was administered to Modi on Monday.

"Made-in-India vaccines are 100% safe," Health Minister Harsh Vardhan said after being inoculated with COVAXIN.

FILE PHOTO: A man receives a Bharat Biotech's COVID-19 vaccine called COVAXIN, at a vaccination centre, in New Delhi, India, February 13, 2021. REUTERS/Adnan Abidi

Many state officials and doctors have refused to take COVAXIN before its effectiveness could be proved. Bharat Biotech says it has completed the late-stage trial and results will be out this month.

The company said the endorsement by Modi and other ministers would set an example for other Indians and reduce "vaccine hesitancy". It is seeking to sell COVAXIN to countries including Brazil and the Philippines.

COVAXIN and the AstraZeneca vaccines were approved by India's regulator in January. The government has distributed to states a total of 50 million doses of the vaccines but only 12% of the 12 million people immunised so far have taken COVAXIN, according to government data https://dashboard.cowin.gov.in.

(Reporting by Krishna N. Das; Additional reporting by Rama Venkat in Bengaluru; Editing by Simon Cameron-Moore)

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.